Showing results (191-200 of 277) with videos related to
Sort By:
Pageof 28
The Journal of Dermatological Treatment|March 23, 2018
Prevalence of genital psoriasis in patients with psoriasisKim A P Meeuwis, Alison Potts Bleakman, Peter C M van de Kerkhof, et al.International Journal of Dermatology|June 7, 2007
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb studyAlan Menter, Tiffani K Hamilton, Darryl P Toth, et al.Journal of the American Academy of Dermatology|September 25, 2004
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trialAlice B Gottlieb, Robert Evans, Shu Li, et al.Journal of Drugs in Dermatology : JDD|August 30, 2013
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label studyAlice B Gottlieb, Robert T Matheson, Alan Menter, et al.Clinical Immunology (Orlando, Fla.)|April 20, 2004
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasisAlice B Gottlieb, Sewon Kang, Kenneth G Linden, et al.International Journal of Dermatology|August 5, 2003
Ciclopirox gel for seborrheic dermatitis of the scalpRaza Aly, H Irving Katz, Steven E Kempers, et al.Acta Dermato-Venereologica|October 18, 2019
Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical TrialLyn Guenther, Alison Potts Bleakman, Jamie Weisman, et al.International Journal of Dermatology|May 17, 2006
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trialKim A Papp, Reni Bressinck, Scott Fretzin, et al.Journal of the American Academy of Dermatology|January 19, 2016
Translating psoriasis guidelines into practice: Important gaps revealedReva Bhushan, Mark G Lebwohl, Alice B Gottlieb, et al.Journal of the American Academy of Dermatology|September 22, 2020
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.Pageof 28